Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230356 · ClinicalTrials.gov registry record · Phase 2
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
A Phase 2 study of Viral Infection and Allogeneic Stell Cell Transplant, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT04230356 is a Phase 2 study of Viral Infection and Allogeneic Stell Cell Transplant that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 180 participants, below the 213-participant average among 11 other Viral Infection trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04230356, a Phase 2 study of Viral Infection and Allogeneic Stell Cell Transplant, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent or treat viral infections that may happen after allogeneic stem cell transplant. Allogeneic means the stem cells come from another person. VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT). Stem cell transplant reduces the body's ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find a better way to treat these infections.
Conditions Studied
Interventions
- BIOLOGICAL Viral Specific T-cells (VSTs) Scheduled
- BIOLOGICAL Viral Specific T-cells (VSTs) Treatment
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230356
The ClinicalTrials.gov registry entry for NCT04230356 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 11 other Viral Infection trials with a reported enrollment target (15% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Viral Infection appearing as the primary indexed condition, and to 2 interventions - of which Viral Specific T-cells (VSTs) Scheduled is the first listed.
NCT04230356 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04230356 about?
NCT04230356 is a clinical study titled "Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant". The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent or treat viral infections that may happen after allogeneic stem cell transplant. Allogeneic means the stem cells come from another person. VSTs are cells specially designed to fight vi...
What is the current status of trial NCT04230356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2021-01-27. Estimated completion is 2028-06.
What conditions does trial NCT04230356 study?
This clinical trial studies the following conditions: Viral Infection, Allogeneic Stell Cell Transplant.
What interventions are being tested in trial NCT04230356?
The interventions under investigation include: Viral Specific T-cells (VSTs) Scheduled (BIOLOGICAL), Viral Specific T-cells (VSTs) Treatment (BIOLOGICAL).
Who is sponsoring clinical trial NCT04230356?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04230356 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Third Party Viral Specific T-cells (VSTs)
RECRUITING · Phase 2
-
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Smell Changes & Efficacy of Nasal Theophylline
COMPLETED · Phase 2
-
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RECRUITING · Phase 1
-
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
RECRUITING · Phase 1
-
School Inner City Air Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.